November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Bitcoin Technical Analysis Points to Potential Bearish Continuation Setup Los Angeles Developer Lists $30 Million Mansion, Open to Anthropic and OpenAI Stock Analyst Advises Divesting From Intel Amid Persistent Growth Headwinds Fiserv Shares Climb Despite Disappointing Third-Quarter 2026 Metrics Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Bitcoin Technical Analysis Points to Potential Bearish Continuation Setup Los Angeles Developer Lists $30 Million Mansion, Open to Anthropic and OpenAI Stock Analyst Advises Divesting From Intel Amid Persistent Growth Headwinds Fiserv Shares Climb Despite Disappointing Third-Quarter 2026 Metrics Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF

PAVmed Shares Surge After Subsidiary Secures Medicare Coverage for Flagship Test

🧠 AI Analysis 2 min read 👁 1

PAVmed Inc. stock jumped over 21% following news that its main subsidiary, Lucid Diagnostics, received nationwide Medicare reimbursement for its EsoGuard test. The medical device firm reported a Q3 non-GAAP adjusted loss of $1.2 million while advancing regulatory pathways across its technology portfolio.

PAVmed Shares Surge After Subsidiary Secures Medicare Coverage for Flagship Test🧠AI Analysis

Photo: Motley Fool

Key points

  • Lucid Diagnostics secured nationwide Medicare claim reimbursement for its EsoGuard test, driving record test volume in October.
  • PAVmed reported a Q3 non-GAAP adjusted loss of $1.2 million while its stock rose 21.73% on the operational milestone.
  • The company is preparing an FDA submission for Veris Health's implantable monitor targeted for early 2027.

PAVmed Inc. shares rose 21.73% following its third-quarter business update, propelled by news that its primary subsidiary, Lucid Diagnostics, secured nationwide Medicare reimbursement for its EsoGuard diagnostic test. The company reported a non-GAAP adjusted loss of $1.2 million for the period, while its GAAP net loss reflected non-cash mark-to-market adjustments on its Lucid holdings. For healthcare investors, obtaining federal coverage represents a major commercial threshold that clears the path for broader adoption and standard reimbursement.

Commercial Expansion and Device Pipeline

Lucid Diagnostics began submitting claims through its laboratory in Texas during late September and has received consistent payments at the full Medicare rate since October. Following the reimbursement decision, the firm redirected its commercial efforts toward Medicare-eligible patients, yielding a record month for test volume in October. Management plans to expand its commercial sales infrastructure to meet demand across the country.

Alongside its esophageal diagnostic business, PAVmed is progressing four main technology divisions:

  • Lucid Diagnostics: Scaling commercial distribution of the EsoGuard test following nationwide Medicare claim approvals.
  • Veris Health: Partnering with Ohio State University to refine clinical workflows ahead of an FDA submission for its implantable oncology monitor in early 2027.
  • PortIO & Octeris: Actively engaging with the FDA to advance regulatory pathways for vascular access and imaging devices.

What to watch next: Investors should monitor quarterly test volume figures for EsoGuard to assess commercial momentum, alongside regulatory updates leading up to Veris Health's 2027 FDA filing.

Source Motley Fool — fool.com/earnings/call-transcripts/2026/11/13/pavmed-pavm-q3-2026-e… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.